1 / 6

Diabetes Therapeutics Market Focus to Boost Revenue with Massive Growth

Global Diabetes Therapeutics Market was valued at $66,993 million in 2016, and is estimated to reach $186,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023.

newmarketindustry
Download Presentation

Diabetes Therapeutics Market Focus to Boost Revenue with Massive Growth

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes Therapeutics Market

  2. According to a report published by Allied Market Research, the Diabetes Therapeutics Market garnered $66.99 billion in 2016 and is estimated to reach $186.84 billion by 2023, growing at a CAGR of 16% from 2017 to 2023. The report offers an extensive analysis of the market drivers, restraints, and opportunities, key investment areas, vital segments, market size & projections, and the competitive landscape. These insights are helpful for market players, investors, stakeholders, and new entrants to understand the market and gain a major market share and international presence Get Sample Report

  3. Increase in prevalence of diabetes worldwide due to increased obesity, urbanization, poor diet, and substandard healthcare conditions in some developing and underdeveloped countries, the development of affordable & effective diabetes therapeutics, growth in awareness among people about self-management of diabetes, and support from the government drive the growth of the market. However, side effects of diabetic drugs and stringent approval process for drugs act as impediments for the growth of the market. Conversely, rise in awareness of diabetes care and untapped market opportunities in developing regions are expected to provide lucrative opportunities for the industry growth.

  4. The report also provides an in-depth analysis of the segments of the diabetes therapeutics market. The industry is segmented based on product and geography. The product segment is bifurcated into injectables and oral-antidiabetic drugs (OAD). The injectables segment is divided into insulin, glucagon-like peptide-1 (GLP-1) receptor agonists/incretin mimetics, and amylin analogue/amylinomimetic drugs. The report offers a comprehensive analysis of the leading players operating in the diabetes therapeutics market. They include Biomedical Diagnostics, BioMerieux, Abbott Laboratories, Bio-Rad, Dako, DiaSorin, Eiken and Fujirebio, Beckman Coulter. They have implemented various strategies such as partnerships, mergers & acquisitions, expansions, collaborations, joint ventures, and others to gain a leadership status in the industry.

  5. Key Findings of the Diabetes Therapeutics Market • The injectables segment accounted for nearly two-thirds share of the global market in 2016. • GLP-1 receptor agonists segment expected to grow at a rapid CAGR of 33.1% from 2017 to 2023. • Insulin segment accounted for more than half of the global market in 2016. • Asia-Pacific is expected to grow at the highest CAGR of 16.8% from 2017 to 2023.

  6. The major companies profiled in the report include AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

More Related